Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.057
Neutral
RSI(14)
48.539
Neutral
STOCH(KDJ)(9,3,3)
20.203
Buy
ATR(14)
0.251
Low Volatility
CCI(14)
-84.736
Neutral
Williams %R
86.170
Oversold
TRIX(12,20)
0.139
Sell
StochRSI(14)
73.310
Buy
MDxHealth SA
MDXH3.530USD
+0.130+3.82%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
174.73MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of MDxHealth SA
Currency: USD Updated: 2026-02-06Key Insights
MDxHealth SA's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered undervalued, ranking 91 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 7.04.In the medium term, the stock price is expected to trend down.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
MDxHealth SA's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
MDxHealth SA Highlights
StrengthsRisks
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 143.02% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 90.05M.
Fairly Valued
The company’s latest PE is -3.54, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 22.89M shares, decreasing 5.52% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 202.80K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.58.
Analyst Rating
Based on
6
analysts
Strong Buy
Current Rating
6.040
Target Price
+325.35%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of MDxHealth SA is 7.31, ranking 122 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 27.43M, representing a year-over-year increase of 17.65%, while its net profit experienced a year-over-year increase of 28.41%.
Score
Financials
6.23
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.62
Operational Efficiency
8.85
Growth Potential
7.63
Shareholder Returns
7.21
MDxHealth SA's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of MDxHealth SA is 7.26, ranking 143 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.54, which is -65.58% below the recent high of -1.22 and -86.23% above the recent low of -6.59.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 91/392
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of MDxHealth SA is 9.00, ranking 15 out of 392 in the Biotechnology & Medical Research industry. The average price target is 7.00, with a high of 9.00 and a low of 4.20.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
6
analysts
Strong Buy
Current Rating
7.040
Target Price
+107.06%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
542
Total
6
Median
6
Average
Company name
Ratings
Analysts
MDxHealth SA
MDXH
6
CRISPR Therapeutics AG
CRSP
29
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Intellia Therapeutics Inc
NTLA
24
Beigene Ltd
ONC
24
1
2
3
...
109
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of MDxHealth SA is 7.21, ranking 90 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 4.25 and the support level at 2.91, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
3.520
Buy
MA10
3.572
Sell
MA20
3.627
Sell
MA50
3.503
Buy
MA100
3.892
Sell
MA200
3.161
Buy
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of MDxHealth SA is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 46.25%, representing a quarter-over-quarter increase of 5.02%. The largest institutional shareholder is James Simons, holding a total of 202.80K shares, representing 0.41% of shares outstanding, with 65.94% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of MDxHealth SA is 2.78, ranking 200 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
--
VaR
--
240-Day Maximum Drawdown
+37.20%
240-Day Volatility
+70.45%
Return
Best Daily Return
60 days
+8.38%
120 days
+13.04%
5 years
--
Worst Daily Return
60 days
-11.81%
120 days
-11.81%
5 years
--
Sharpe Ratio
60 days
-1.22
120 days
+1.02
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+37.20%
3 years
+68.53%
5 years
--
Return-to-Drawdown Ratio
240 days
+2.58
3 years
+0.12
5 years
--
Skewness
240 days
+0.33
3 years
+0.34
5 years
--
Volatility
Realised Volatility
240 days
+70.45%
5 years
--
Standardised True Range
240 days
+5.15%
5 years
--
Downside Risk-Adjusted Return
120 days
+175.93%
240 days
+175.93%
Maximum Daily Upside Volatility
60 days
+45.21%
Maximum Daily Downside Volatility
60 days
+50.32%
Liquidity
Average Turnover Rate
60 days
+0.21%
120 days
+0.17%
5 years
--
Turnover Deviation
20 days
+57.95%
60 days
-6.69%
120 days
-22.06%
Peer Comparison
Biotechnology & Medical Research
MDxHealth SA
MDXH
6.74 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ionis Pharmaceuticals Inc
IONS
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
